Related Experiment Videos
Creutzfeldt-Jakob disease: implications for growth hormone deficient children
Insights
Human growth hormone (hGH) injections, used for 25 years to treat short stature, have been halted. This follows four deaths from Creutzfeldt-Jakob disease (CJD), posing significant risks and treatment challenges.
Area of Science:
- Pediatric Endocrinology
- Neurology
- Public Health
Background:
- Human growth hormone (hGH) injections were a standard treatment for children with short stature due to growth hormone deficiency for over two decades.
- This established therapy has been discontinued following adverse events.
Purpose of the Study:
- To address the implications of the cessation of human growth hormone (hGH) treatment.
- To highlight the risks associated with Creutzfeldt-Jakob disease (CJD) transmission through hGH therapy.
- To underscore the urgent need for alternative treatments for growth disorders.
Main Methods:
- Review of reported cases linking hGH treatment to Creutzfeldt-Jakob disease (CJD).
- Analysis of the safety profile of past hGH therapies.
- Assessment of the therapeutic gap created by the discontinuation of hGH.
Main Results:
- Four deaths in young adults were reported, linked to Creutzfeldt-Jakob disease (CJD) in individuals treated with hGH.
- The established hGH treatment for short stature has been consequently stopped.
- Significant public health concerns arise regarding potential further CJD cases.
Conclusions:
- The cessation of hGH therapy presents major implications for patients with growth deficiencies.
- The risk of further Creutzfeldt-Jakob disease (CJD) cases necessitates stringent monitoring and preventative measures.
- The lack of a proven alternative therapeutic substitute creates a critical unmet medical need.
Abstract:
For over 25 years children with short stature due to growth hormone deficiency have been able to achieve normal height with the aid of human growth hormone (hGH) injections. Following reports of four deaths due to Creutzfeldt-Jakob disease (CJD) in young adults previously treated with hGH this treatment has ceased. There are major implications due to the potential risks of further cases of CJD and to the lack of a previously well-tried therapeutic substitute.